Role of Sympathetic Activation in Ischemia Reperfusion Injury

Royal Perth Hospital

Status and phase: Completed; Phase 4

Conditions: Central Sympathetic Nervous System Diseases

Treatments: Drug: Moxonidine 0.2 MG; Other: placebo

Study type: Interventional

Funder types: Other

Identifiers

NCT04479813

REG 15-021

Details and patient eligibility

About

This study is designed to assess the effect of forearm ischemia-reperfusion injury on sympathetic nerve activity. To determine whether reduced sympathetic responsiveness is a contributor to the protective effects of remote ischemic preconditioning. In addition it will assess whether pharmacologic inhibition of the sympathetic nervous system can ameliorate ischemia reperfusion injury induced endothelial dysfunction.

Full description

This is a randomized single blind study where subjects will be allocated to undergo one of the 4 protocols. Participants will be given placebo or 0.2mg of Moxonidine to take orally 20 minutes prior to the first endothelial function measurement.

This medication acts by reducing the activity of nerves believed to be involved in the conditioning process. The placebo pill, designed to have no effect, will be used as a comparison. Comprehensive tests will occur which include Microneurography, Endothelial function ,Blood Sampling, Temporary block of arm blood flow and Remote conditioning

Enrollment: 46 patients

Sex: Male

Ages: 18 to 75 years old

Volunteers: Accepts Healthy Volunteers

Inclusion criteria

• healthy males, not on any medication, free of any history of metabolic, cardiovascular or cerebrovascular disease.

Exclusion criteria

• smoker

Trial design

Primary purpose: Basic Science

Allocation: Randomized

Interventional model: Factorial Assignment

Masking: Single Blind

---

46 participants in 4 patient groups

No conditioning + placebo

Experimental group

Description:

Participants will be given placebo to take orally 20 minutes prior to the first endothelial function measurement without conditioning tests.

Treatment:

Other: placebo

No conditioning + moxonidine

Experimental group

Description:

Participants will be given moxonidine to take orally 20 minutes prior to the first endothelial function measurement without conditioning tests.

Treatment:

Drug: Moxonidine 0.2 MG

Remote pre-conditioning + placebo

Experimental group

Description:

Participants will be given placebo to take orally 20 minutes prior to the first endothelial function measurement with conditioning tests.

Treatment:

Other: placebo

Remote pre-conditioning + moxonidine

Experimental group

Description:

Participants will be given moxonidine to take orally 20 minutes prior to the first endothelial function measurement with conditioning tests.

Treatment:

Drug: Moxonidine 0.2 MG